老虎證券

BRIEF-Prokidney Announces Alignment With The FDA On The Accelerated Approval Pathway For Rilparencel

Reuters
07-15
BRIEF-Prokidney Announces Alignment With The FDA On The Accelerated Approval Pathway For Rilparencel

July 15 (Reuters) - ProKidney Corp PROK.O:

  • PROKIDNEY ANNOUNCES ALIGNMENT WITH THE FDA ON THE ACCELERATED APPROVAL PATHWAY FOR RILPARENCEL

  • PROKIDNEY CORP - FDA CONFIRMS EGFR SLOPE AS SURROGATE ENDPOINT FOR RILPARENCEL IN PATIENTS WITH CKD & TYPE 2 DIABETES

  • PROKIDNEY CORP - TOPLINE DATA FOR ACCELERATED APPROVAL EXPECTED IN Q2 2027

  • PROKIDNEY CORP - FDA CONFIRMS PHASE 3 PROACT 1 STUDY CAN BE USED FOR BOTH ACCELERATED APPROVAL & FOR FULL APPROVAL

Source text: ID:nGNX5bQsS8

Further company coverage: PROK.O

((Reuters.Briefs@thomsonreuters.com;))

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10